The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours

Hillel, P. G.; Beek, Edwin Jacques Rudolph van; Taylor, Carolyn; Lorenz, Eleanor; Bax, N. D. S.; Prakash, Vineet; Tindale, W. B.

doi:10.1016/j.crad.2006.04.001

Cited by 64 publications

(32 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No additional information beyond that provided by planar imaging or SPECT was achieved for 48 patients, whereas SPECT/CT improved the localization of scintigraphic findings for 23 patients (32%) and changed clinical management for 14% of patients. (55). The addition of clinically relevant information for 40% of patients by SPECT/CT compared with SPECT was described by Gabriel et al (56).…”

Section: Spect/ct In Neuroendocrine Tumorsmentioning

confidence: 99%

Spect/Ct

Buck¹,

Nekolla²,

Ziegler³

et al. 2008

J Nucl Med

281

149

View full text Add to dashboard Cite

In view of the commercial success of integrated PET/CT scanners, there is an increasing interest in comparable SPECT/CT systems. SPECT in combination with CT enables a direct correlation of anatomic information and functional information, resulting in better localization and definition of scintigraphic findings. Besides anatomic referencing, the added value of CT coregistration is based on the attenuation correction capabilities of CT. The number of clinical studies is limited, but pilot studies have indicated a higher specificity and a significant reduction in indeterminate findings. The superiority of SPECT/CT over planar imaging or SPECT has been demonstrated in bone scintigraphy, somatostatin receptor scintigraphy, parathyroid scintigraphy, and adrenal gland scintigraphy. Also, rates of detection of sentinel nodes by biopsy can be increased with SPECT/CT. This review highlights recent technical developments in integrated SPECT/CT systems and summarizes the current literature on potential clinical uses and future directions for SPECT/CT in cardiac, neurologic, and oncologic applications.

show abstract

Section: Spect/ct In Neuroendocrine Tumorsmentioning

confidence: 99%

Spect/Ct

Buck¹,

Nekolla²,

Ziegler³

et al. 2008

J Nucl Med

281

149

View full text Add to dashboard Cite

show abstract

“…98,99 In a recent study of 15 NET patients with abnormal SRS findings, a further examination with a 111 In-Pentetreotide SPECT/CT imaging system revealed previously unidentified lesions in 7 and altered tumor location in 4 individuals. 100 PET/ CT altered staging in 5 of 29, and the sensitivity for accurate staging of patients with extensive SCLC disease was 93% for PET and 93% for PET/CT, whereas the specificity was 83% and 100%, respectively. 101 …”

Section: Combined Techniquesmentioning

confidence: 98%

Bronchopulmonary neuroendocrine tumors

Gustafsson

Kidd

Chan

et al. 2008

Cancer

445

340

View full text Add to dashboard Cite

SCLC is the most common BP-NET, while LCNEC is rare, %10% and 1%, respectively, of all lung cancers. Both SCLC and LCNEC progress rapidly, are aggressively metastatic, and exhibit a poor prognosis. The incidence of BP-carcinoids (TC and AC) in the US was 1.57 of 100,000 in 2003 (an unexplained and substantial increase over the last 30 years, %6% per year). No curative treatment except for radical surgery (almost never feasible) exists. The slow-growing TC exhibit a fairly good prognosis (%88%, 5-year survival), whereas AC demonstrate a 5-year survival of %50%, and the highly malignant LCNEC and SCLC 5-year survival of 15% to 57% and <5%, respectively. This review provides a broad overview on BPNETs and focuses on the evolution of the disease, general features, and current diagnostic and therapeutic options.

show abstract

“…The clinical impact of SPECT/CT hybrid imaging on SRS studies was retrospectively assessed in 29 patients with known or suspected NETs, to evaluate the extent of disease and thus obtain guidance for the patients' future management [31]. Fifteen out of 29 SPECT-alone studies showed abnormalities.…”

Section: In-111 Pentetreotide Spect/ctmentioning

confidence: 99%

SPECT/CT in neuroendocrine tumours

Schillaci

Spanu

Palumbo

et al. 2014

Clin Transl Imaging

View full text Add to dashboard Cite

Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms with very varying clinical expressions. Nuclear medicine plays an important role in the imaging and treatment of these tumours. Despite the advent of several PET radiopharmaceuticals, SPECT imaging with the labelled somatostatin receptor analogue In-111 pentetreotide or with radioiodinated MIBG is still a very useful technique for evaluating patients with NETs. The aim of this review is to summarise the applications, in the study of NETs, of hybrid SPECT/CT imaging performed using these gamma-emitting radiopharmaceuticals. The combined use of SPECT and CT in hybrid devices is of value when applied to scintigraphic procedures in NETs: the addition of anatomical maps provides a precise localisation of SPECT findings and allows the exclusion of disease in sites of physiological tracer uptake. These advantages translate into better sensitivity and specificity, both of which are essential for the diagnosis and accurate staging of NETs. SPECT/CT hybrid images are able to provide additional information that improves the diagnostic accuracy and confidence of SPECT interpretation and leads to changes in therapeutic options in about 25 % of patients. Therefore, SPECT/CT should be routinely performed and considered standard practice in the diagnostic work-up and treatment planning of patients with NETs submitted to In-111 pentetreotide or radioiodinated MIBG imaging. This approach can still be used as an alternative to PET/CT options when the latter are not available.

show abstract

The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours

Cited by 64 publications

References 12 publications

Spect/Ct

Spect/Ct

Bronchopulmonary neuroendocrine tumors

SPECT/CT in neuroendocrine tumours

Contact Info

Product

Resources

About